Albireo Pharma
This sponsor has funded 1 studies across 23 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 106243 | Ongoing | Prospective Registry-Based Study of the Long-Term Safety of Odeevixibat in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) | No | No |
PAS by Risk Management Plan (RMP) requirement
Albireo Pharma
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Albireo Pharma
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Albireo Pharma
23 Study countries specified are the following:
- Austria
- Belgium
- Brazil
- Canada
- China
- France
- Hungary
- India
- Ireland
- Israel
- Italy
- Netherlands
- Poland
- Portugal
- Slovenia
- South Africa
- Spain
- Sweden
- Switzerland
- Türkiye
- United Arab Emirates
- United Kingdom
- United States